These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 18480694)

  • 1. Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study.
    George TP; Sacco KA; Vessicchio JC; Weinberger AH; Shytle RD
    J Clin Psychopharmacol; 2008 Jun; 28(3):340-4. PubMed ID: 18480694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant.
    Vieta E; Thase ME; Naber D; D'Souza B; Rancans E; Lepola U; Olausson B; Szamosi J; Wilson E; Hosford D; Dunbar G; Tummala R; Eriksson H
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):564-74. PubMed ID: 24507016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
    Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ;
    J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder.
    Iosifescu DV; Nierenberg AA; Mischoulon D; Perlis RH; Papakostas GI; Ryan JL; Alpert JE; Fava M
    J Clin Psychiatry; 2005 Aug; 66(8):1038-42. PubMed ID: 16086620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness.
    Fava M; Thase ME; DeBattista C
    J Clin Psychiatry; 2005 Jan; 66(1):85-93. PubMed ID: 15669893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder.
    Papakostas GI; Petersen TJ; Nierenberg AA; Murakami JL; Alpert JE; Rosenbaum JF; Fava M
    J Clin Psychiatry; 2004 Feb; 65(2):217-21. PubMed ID: 15003076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (S)-(+)-mecamylamine (TC-5214): a neuronal nicotinic receptor modulator enters phase III trials as an adjunct treatment for Major Depressive Disorder (MDD).
    Lindsley CW
    ACS Chem Neurosci; 2010 Aug; 1(8):530-1. PubMed ID: 22778844
    [No Abstract]   [Full Text] [Related]  

  • 8. Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial.
    Perry EB; Berman RM; Sanacora G; Anand A; Lynch-Colonese K; Charney DS
    J Clin Psychiatry; 2004 Feb; 65(2):238-43. PubMed ID: 15003079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the Efficacy and Safety of Aripiprazole Versus Bupropion Augmentation in Patients With Major Depressive Disorder Unresponsive to Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-Label Study.
    Cheon EJ; Lee KH; Park YW; Lee JH; Koo BH; Lee SJ; Sung HM
    J Clin Psychopharmacol; 2017 Apr; 37(2):193-199. PubMed ID: 28129308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study.
    Ozaki N; Otsubo T; Kato M; Higuchi T; Ono H; Kamijima K;
    Psychiatry Clin Neurosci; 2015 Jan; 69(1):34-42. PubMed ID: 24965202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
    Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
    Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of selective serotonin reuptake inhibitors in healthy first-degree relatives of patients with major depressive disorder - an experimental medicine blinded controlled trial.
    Knorr UB
    Dan Med J; 2012 Apr; 59(4):B4426. PubMed ID: 22459724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression.
    Portella MJ; de Diego-Adeliño J; Ballesteros J; Puigdemont D; Oller S; Santos B; Álvarez E; Artigas F; Pérez V
    J Clin Psychiatry; 2011 Jul; 72(7):962-9. PubMed ID: 21034693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder.
    Papakostas GI; Petersen TJ; Kinrys G; Burns AM; Worthington JJ; Alpert JE; Fava M; Nierenberg AA
    J Clin Psychiatry; 2005 Oct; 66(10):1326-30. PubMed ID: 16259548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.
    Preskorn SH; Baker B; Kolluri S; Menniti FS; Krams M; Landen JW
    J Clin Psychopharmacol; 2008 Dec; 28(6):631-7. PubMed ID: 19011431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment-emergent suicidal ideation during 4 months of acute management of unipolar major depression with SSRI pharmacotherapy or interpersonal psychotherapy in a randomized clinical trial.
    Rucci P; Frank E; Scocco P; Calugi S; Miniati M; Fagiolini A; Cassano GB
    Depress Anxiety; 2011 Apr; 28(4):303-9. PubMed ID: 21308882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.
    Ball SG; Ferguson MB; Martinez JM; Pangallo BA; Nery ES; Dellva MA; Sparks J; Zhang Q; Liu P; Bangs M; Goldberger C
    J Clin Psychiatry; 2016 May; 77(5):635-42. PubMed ID: 27035159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine.
    Nierenberg AA; Loft H; Olsen CK
    J Affect Disord; 2019 May; 250():35-42. PubMed ID: 30826492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder.
    Lyoo IK; Yoon S; Kim TS; Hwang J; Kim JE; Won W; Bae S; Renshaw PF
    Am J Psychiatry; 2012 Sep; 169(9):937-945. PubMed ID: 22864465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial.
    Papakostas GI; Mischoulon D; Shyu I; Alpert JE; Fava M
    Am J Psychiatry; 2010 Aug; 167(8):942-8. PubMed ID: 20595412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.